Cardlytics Inc (NASDAQ: CDLX)’s stock price has decreased by -1.97 compared to its previous closing price of 12.18. However, the company has seen a -16.97% decrease in its stock price over the last five trading sessions. The Motley Fool reported 2024-04-02 that Cardlytics stock skyrocketed because its business showed improved trends. The company then refinanced some of its debt at a higher rate, which troubled investors.
Is It Worth Investing in Cardlytics Inc (NASDAQ: CDLX) Right Now?
The 36-month beta value for CDLX is also noteworthy at 1.51. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 1 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for CDLX is 41.10M, and at present, short sellers hold a 14.48% of that float. The average trading volume of CDLX on April 19, 2024 was 1.78M shares.
CDLX’s Market Performance
The stock of Cardlytics Inc (CDLX) has seen a -16.97% decrease in the past week, with a -15.32% drop in the past month, and a 94.46% gain in the past quarter. The volatility ratio for the week is 5.86%, and the volatility levels for the past 30 days are at 10.17% for CDLX. The simple moving average for the last 20 days is -16.16% for CDLX stock, with a simple moving average of 11.09% for the last 200 days.
Analysts’ Opinion of CDLX
Many brokerage firms have already submitted their reports for CDLX stocks, with Craig Hallum repeating the rating for CDLX by listing it as a “Buy.” The predicted price for CDLX in the upcoming period, according to Craig Hallum is $18 based on the research report published on March 15, 2024 of the current year 2024.
Lake Street, on the other hand, stated in their research note that they expect to see CDLX reach a price target of $13. The rating they have provided for CDLX stocks is “Buy” according to the report published on November 29th, 2023.
Wells Fargo gave a rating of “Underweight” to CDLX, setting the target price at $13 in the report published on September 08th of the previous year.
CDLX Trading at 14.17% from the 50-Day Moving Average
After a stumble in the market that brought CDLX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -41.81% of loss for the given period.
Volatility was left at 10.17%, however, over the last 30 days, the volatility rate increased by 5.86%, as shares sank -21.50% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +80.91% upper at present.
During the last 5 trading sessions, CDLX fell by -16.97%, which changed the moving average for the period of 200-days by +89.83% in comparison to the 20-day moving average, which settled at $14.08. In addition, Cardlytics Inc saw 29.64% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CDLX starting from Temsamani Karim Saad, who sale 32,564 shares at the price of $13.69 back on Apr 02 ’24. After this action, Temsamani Karim Saad now owns 344,734 shares of Cardlytics Inc, valued at $445,801 using the latest closing price.
Lynton Nicholas Hollmeyer, the Chief Legal & Privacy Officer of Cardlytics Inc, sale 12,460 shares at $13.69 during a trade that took place back on Apr 02 ’24, which means that Lynton Nicholas Hollmeyer is holding 71,355 shares at $170,620 based on the most recent closing price.
Stock Fundamentals for CDLX
Current profitability levels for the company are sitting at:
- -0.28 for the present operating margin
- 0.43 for the gross margin
The net margin for Cardlytics Inc stands at -0.37. The total capital return value is set at -0.22. Equity return is now at value -77.77, with -21.29 for asset returns.
Based on Cardlytics Inc (CDLX), the company’s capital structure generated 0.66 points at debt to capital in total, while cash flow to debt ratio is standing at -0.0. The debt to equity ratio resting at 1.93. The interest coverage ratio of the stock is -14.32.
Currently, EBITDA for the company is -34.15 million with net debt to EBITDA at -4.0. When we switch over and look at the enterprise to sales, we see a ratio of 2.24. The receivables turnover for the company is 2.48for trailing twelve months and the total asset turnover is 0.54. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.31.
Conclusion
In summary, Cardlytics Inc (CDLX) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
